CCM
NVLN

Context Capital Management’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Context Capital Management’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-42,534
Closed -$52K – 95
2019
Q1 		$52K Sell
42,534
-21,200
-33% -$24.1K 0.03% 76
2018
Q4 		$54K Hold
63,734
– – 0.03% 76
2018
Q3 		$189K Buy
+63,734
New +$226K 0.11% 67

Other funds holding NVLN

EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return
FSA
Franklin Street Advisors Chapel Hill, North Carolina $1.79B AUM 28.1% 1-Year Est. Return

Context Capital Management's NVLN Position: Q2 2019 in Review

Context Capital Management sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q2 2019, closing a stake of 42,534 shares — an estimated $52K sold.

Context Capital Management first reported a position in NVLN in Q3 2018 and held it in 3 quarters. The position peaked at $189K in Q3 2018. 35 funds tracked by Wall St. Rank hold NVLN as of Q2 2019.

  • Context Capital Management reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q2 2019 after selling out during the quarter.
  • Context Capital Management sold 42,534 Novelion Therapeutics Inc. Common Shares shares in Q2 2019, an estimated $52K.
  • Context Capital Management first reported a position in Novelion Therapeutics Inc. Common Shares in Q3 2018 and held it in 3 quarters.
  • Context Capital Management's Novelion Therapeutics Inc. Common Shares position peaked at $189K in Q3 2018.
  • 35 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q2 2019.

Based on Context Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.